GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS



BIO021D October 2013

Shalini Shahani Dewan **Project Analyst**

ISBN: 1-56965-566-9



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

| TOPIC | PAGE NO. |
|---|----------|
| CHAPTER 1 INTRODUCTION | 2 |
| STUDY OBJECTIVES | 2 |
| REASONS FOR DOING THIS STUDY | 2 |
| INTENDED AUDIENCE | 2 |
| SCOPE OF THE STUDY | 2 |
| METHODOLOGY | 3 |
| INFORMATION SOURCES | 3 |
| ABOUT THE AUTHOR | 3 |
| RELATED BCC RESEARCH REPORTS | 4 |
| BCC ONLINE SERVICES | 4 |
| DISCLAIMER | 4 |
| CHAPTER 2 SUMMARY | 6 |
| SUMMARY TABLE GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, | 6 |
| THROUGH 2018 (\$ MILLIONS) | 6 |
| SUMMARY FIGURE GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, 2011-2018 (\$ MILLIONS) | 7 |
| CHAPTER 3 OVERVIEW | 9 |
| DEFINITIONS | 9 |
| HISTORY | 9 |
| TABLE 1 EVOLUTION OF THERAPEUTIC PROTEINS | 10 |
| PHARMACOLOGICAL CLASSIFICATION OF THERAPEUTIC PROTEINS | 11 |
| PROTEIN THERAPEUTICS WITH ENZYMATIC OR REGULATORY ACTIVITY | 11 |
| PROTEIN THERAPEUTICS WITH SPECIAL TARGETED ACTIVITY | 12 |
| PROTEIN VACCINES | 12 |
| MANUFACTURING TECHNOLOGIES | 12 |
| NATURAL SOURCING AND EXTRACTION | 13 |
| TABLE 2 PROTEIN DRUGS MADE BY HUMAN SOURCE EXTRACTION | 13 |
| TABLE 3 PROTEIN DRUGS MADE BY ANIMAL SOURCE EXTRACTION | 14 |
| MICROBIAL FERMENTATION | 15 |
| TABLE 4 PROTEIN DRUGS MADE BY MICROBIAL FERMENTATION | 16 |
| TRANSGENICS | 16 |
| TABLE 5 PROTEIN DRUGS MADE BY TRANSGENIC ORGANISMS | 17 |
| MAMMALIAN CELL CULTURE | 17 |
| TABLE 6 PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE | 18 |
| OTHER CELL CULTURE SYSTEMS | 18 |
| TABLE 7 PROTEIN DRUGS MADE BY INSECT CELL CULTURE | 18 |
| MOLECULAR CLASSIFICATION OF THERAPEUTIC PROTEINS | 18 |
| CYTOKINES | 19 |
| Colony-stimulating Factors | 19 |
| Interferons Interleukins | 19 20 |
| ANTIBODIES | 20 |
| BLOOD PRODUCTS | 20 |
| Alpha-1- Proteinase Inhibitor | 21 |
| = | |

| TOPIC | PAGE NO. |
|---|----------|
| Antihemophilic Factor | 21 |
| Antithrombin | 22 |
| C1 Esterase Inhibitor | 22 |
| Coagulation Factors | 23 |
| Immuno-Globulins | 23 |
| Protein C | 24 |
| Thrombin | 24 |
| PEPTIDE ANTIBIOTICS | 25 |
| VACCINES | 25 |
| ENZYMES | 26 |
| Digestive Enzymes | 27 |
| Lysosomal Enzymes | 27 |
| Thrombolytic Enzymes | 28 |
| Other Enzymes | 28 |
| PEPTIDE HORMONES | 28 |
| Follicle-stimulating Hormone and Luteinizing Hormone | 29 |
| Adrenocorticotropic Hormone | 29 |
| Growth Hormones | 29 |
| Erythropoietin | 29 |
| Insulin | 30 |
| | |
| CHAPTER 4 REGULATORY ASPECTS | 32 |
| MONOCLONAL ANTIBODIES | 32 |
| TABLE 8 NEW APPROVALS OF MONOCLONAL ANTIBODIES (2009-JUNE 2013) | 32 |
| THERAPEUTIC ENZYMES | 34 |
| TABLE 9 NEW APPROVALS OF THERAPEUTIC ENZYMES (2009-JUNE 2013) | 34 |
| CYTOKINES TABLE 10 NEW APPROVALS OF CYTOKINES (2000 WATE 2012) | 35 |
| TABLE 10 NEW APPROVALS OF CYTOKINES (2009-JUNE 2013) | 36 |
| VACCINES TABLE 11 NEW APPROVALS OF MASSINES (2000, MANE 2012) | 36 |
| TABLE 11 NEW APPROVALS OF VACCINES (2009–JUNE 2013) BLOOD FACTORS | 36 |
| | 39 |
| TABLE 12 NEW APPROVALS OF BLOOD FACTORS (2009-JUNE 2013) PEPTIDE HORMONES | 39 42 |
| TABLE 13 NEW APPROVALS OF PEPTIDE HORMONES (2009- JUNE 2013) | 42 |
| NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS | 42 |
| TABLE 14 NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS | 42 |
| (2009-JUNE 2013) | 43 |
| RECALLS | 44 |
| TABLE 15 RECALLS (2009-JUNE 2013) | 45 |
| SAFETY ALERTS | 48 |
| TABLE 16 SAFETY ALERTS (2009-JUNE 2013) | 49 |
| | |
| CHAPTER 5 NEW DEVELOPMENTS | 52 |
| BLOOD PRODUCTS | 52 |
| TABLE 17 NEW DEVELOPMENTS/CLINICAL TRIALS IN BLOOD PRODUCTS | 53 |
| VACCINES | 55 |
| TABLE 18 NEW DEVELOPMENTS/CLINICAL TRIALS IN VACCINES | 55 |
| PEPTIDE HORMONES | 58 |

| TOPIC | PAGE NO. |
|---|----------|
| TABLE 19 NEW DEVELOPMENTS/CLINICAL TRIALS IN PEPTIDE HORMONES | 58 |
| PEPTIDE ANTIBIOTICS | 60 |
| TABLE 20 NEW DEVELOPMENTS/CLINICAL TRIALS IN PEPTIDE ANTIBIOTICS | 61 |
| CYTOKINES | 62 |
| TABLE 21 NEW DEVELOPMENTS/CLINICAL TRIALS IN CYTOKINES | 63 |
| MONOCLONAL ANTIBODIES | 64 |
| TABLE 22 NEW DEVELOPMENTS/CLINICAL TRIALS IN MONOCLONAL ANTIBODIES | 65 |
| THERAPEUTIC ENZYMES | 70 |
| TABLE 23 NEW DEVELOPMENTS/CLINICAL TRIALS IN ENZYMES | 71 |
| | |
| CHAPTER 6 GLOBAL MARKETS | 73 |
| MARKETS BY TYPE | 74 |
| MARKET OVERVIEW | 75 |
| MARKET REVENUE | 79 |
| TABLE 24 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPE, THROUGH 2018 (\$ MILLIONS) | 79 |
| FIGURE 1 GLOBAL MARKET FOR PROTEIN THERAPEUTICS, BY TYPE, THROUGH 2018 (\$ MILLIONS) | 79 |
| MARKET SHARE | 80 |
| TABLE 25 MARKET SHARE OF PROTEIN THERAPEUTICS, BY TYPE, 2012 (%) | 80 |
| FIGURE 2 MARKET SHARE OF PROTEIN THERAPEUTICS, BY TYPE, 2012 (%) | 80 |
| MARKET BY REGION | 81 |
| MARKET OVERVIEW | 82 |
| MARKET REVENUE | 84 |
| TABLE 26 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY REGION, THROUGH 2018 (\$ MILLIONS) | 84 |
| FIGURE 3 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY REGION, 2011-2018 (\$ MILLIONS) | 84 |
| MARKET SHARE | 85 |
| TABLE 27 MARKET SHARE OF PROTEIN THERAPEUTICS, BY REGION, 2012 (%) | 85 |
| FIGURE 4 MARKET SHARE OF PROTEIN THERAPEUTICS, BY REGION, 2012 (%) | 85 |
| MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES | 85 |
| Market Overview | 86 |
| Market Revenue | 86 |
| TABLE 28 GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, THROUGH 2018 (\$ MILLIONS) | 87 |
| FIGURE 5 GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, 2011-2018 (\$ MILLIONS) | 87 |
| Market Share | 87 |
| TABLE 29 MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, 2012 (%) | 88 |
| FIGURE 6 MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, 2012 (%) | 88 |
| MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES | 88 |
| Market Overview | 89 |
| Market Revenue | 89 |
| TABLE 30 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) | 90 |

| TOPIC | PAGE NO. |
|--|----------|
| FIGURE 7 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) | 90 |
| Market Share | 91 |
| TABLE 31 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) | 91 |
| FIGURE 8 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) | 91 |
| MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS | 91 |
| Market Overview | 92 |
| Market Revenue | 93 |
| TABLE 32 GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2018 (\$ MILLIONS) | 93 |
| FIGURE 9 GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, 2011-2018 (\$ MILLIONS) | 93 |
| Market Share | 94 |
| TABLE 33 MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, 2012 (%) | 94 |
| FIGURE 10 MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, 2012 (%) | 94 |
| MARKET BY MANUFACTURING PROCESS | 95 |
| MARKET OVERVIEW | 97 |
| MARKET REVENUE | 99 |
| TABLE 34 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 99 |
| FIGURE 11 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) | 100 |
| MARKET SHARE | 100 |
| TABLE 35 MARKET SHARE OF PROTEIN THERAPEUTICS BY TYPE OF MANUFACTURING PROCESS, 2012 (%) | 100 |
| FIGURE 12 MARKET SHARE OF PROTEIN THERAPEUTICS BY TYPE OF MANUFACTURING PROCESS, 2012 (%) | 101 |
| CHAPTER 7 PEPTIDE HORMONES AND THERAPEUTIC ENZYMES | 103 |
| MARKET BY TYPE | 103 |
| MARKET OVERVIEW | 103 |
| MARKET REVENUE | 104 |
| TABLE 36 GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES, THROUGH 2018 (\$ MILLIONS) | 104 |
| FIGURE 13 GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES, 2011-2018 (\$ MILLIONS) | 104 |
| MARKET SHARE | 105 |
| TABLE 37 MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES, 2012 (%) | 105 |
| FIGURE 14 MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES, 2012 (%) | 105 |
| MARKET FOR PEPTIDE HORMONES | 106 |
| Market Overview | 106 |
| Market Revenue | 107 |
| TABLE 38 GLOBAL MARKET FOR PEPTIDE HORMONES BY TYPE, THROUGH 2018 (\$ MILLIONS) | 108 |
| FIGURE 15 GLOBAL MARKET FOR PEPTIDE HORMONES BY TYPE, 2011-2018 (\$ MILLIONS) | 108 |

| TOPIC | PAGE NO. |
|---|----------|
| Market Share | 109 |
| TABLE 39 MARKET SHARE OF PEPTIDE HORMONES BY TYPE, 2012 (%) | 109 |
| FIGURE 16 MARKET SHARE OF PEPTIDE HORMONES BY TYPE, 2012 (%) | 109 |
| MARKET FOR THERAPEUTIC ENZYMES | 109 |
| Market Overview | 110 |
| Market Revenue | 110 |
| TABLE 40 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY TYPE, THROUGH 2018 (\$ MILLIONS) | 111 |
| FIGURE 17 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY TYPE, THROUGH 2018 (\$ MILLIONS) | 111 |
| Market Share | 112 |
| TABLE 41 MARKET SHARE OF THERAPEUTIC ENZYMES BY TYPE, 2012 (%) | 112 |
| FIGURE 18 MARKET SHARE OF THERAPEUTIC ENZYMES BY TYPE, 2012 (%) | 112 |
| MARKET BY REGION | 112 |
| PEPTIDE HORMONES | 113 |
| Market Overview | 113 |
| Market Revenue | 114 |
| TABLE 42 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, THROUGH 2018 (\$ MILLIONS) | 114 |
| FIGURE 19 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, THROUGH 2018 (\$ MILLIONS) | 114 |
| Market Share | 115 |
| TABLE 43 MARKET SHARE OF PEPTIDE HORMONES BY REGION, 2012 (%) | 115 |
| FIGURE 20 MARKET SHARE OF PEPTIDE HORMONES BY REGION, 2012 (%) | 115 |
| THERAPEUTIC ENZYMES | 115 |
| Market Overview | 116 |
| Market Revenue | 116 |
| TABLE 44 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, THROUGH 2018 (\$ MILLIONS) | 117 |
| FIGURE 21 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, 2011-2018 (\$ MILLIONS) | 117 |
| Market Share | 118 |
| TABLE 45 MARKET SHARE OF THERAPEUTIC ENZYMES BY REGION, 2012 (%) | 118 |
| FIGURE 22 MARKET SHARE OF THERAPEUTIC ENZYMES BY REGION, 2012 (%) | 118 |
| MARKET BY MANUFACTURING PROCESS | 118 |
| PEPTIDE HORMONES | 119 |
| Market Overview | 119 |
| Market Revenue | 120 |
| TABLE 46 GLOBAL MARKET FOR PEPTIDE HORMONES BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 121 |
| FIGURE 23 GLOBAL MARKET FOR PEPTIDE HORMONES BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) | 121 |
| Market Shares | 121 |
| TABLE 47 MARKET SHARE OF PEPTIDE HORMONES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 122 |
| FIGURE 24 MARKET SHARE OF PEPTIDE HORMONES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 122 |
| THERAPEUTIC ENZYMES | 122 |
| Market Overview | 123 |

| TABLE 48 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) FIGURE 25 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) Market Share TABLE 49 MARKET SHARE OF ENZYMES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) FIGURE 26 MARKET SHARE OF ENZYMES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) INDUSTRY STRUCTURE PEPTIDE HORMONES Market Leaders TABLE 50 PEPTIDE HORMONES Market Share TABLE 50 PEPTIDE HORMONES Market Share TABLE 51 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) THERAPEUTIC ENZYMES TABLE 52 THERAPEUTIC ENZYMES Market Share TABLE 53 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) THERAPEUTIC ENZYMES TABLE 53 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) FIGURE 27 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE MARKET OVERVIEW MARKET OVERVIEW MARKET OVERVIEW MARKET REVENUE TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (5 MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (5 MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (5 MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (5 MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES BY TYPE, 111-2014 (5 MILLIONS) MARKET SHARE TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (5 MILLIONS) MARKET SHARE TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (5 MILLIONS) MARKET SHARE TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | TOPIC | PAGE NO. |
|---|--|----------|
| MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) FIGURE 25 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) Market Share TABLE 49 MARKET SHARE OF ENZYMES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) FIGURE 26 MARKET SHARE OF ENZYMES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) FIGURE 26 MARKET SHARE OF ENZYMES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) FIDURE 26 MARKET SHARE OF ENZYMES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) INDUSTRY STRUCTURE PEPTIDE HORMONES Market Leaders TABLE 50 PEPTIDE HORMONES Market Share TABLE 51 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) FIGURE 27 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) THERAPEUTIC ENZYMES TABLE 52 THERAPEUTIC ENZYMES TABLE 52 THERAPEUTIC ENZYMES TABLE 52 THERAPEUTIC ENZYMES TABLE 53 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE MARKET OVERVIEW MARKET TOVERVIEW MARKET TOVERVIEW MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET MARKET SHARE OF CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) MARKET REVENUE TABLE 55 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) MARKET REVENUE MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET MONOCLONAL ANTIBODIES BY TYPE, 2012 (%) HOURD STARMENT SHARE OF CYTOKINES BY TYPE, 2012 (%) HOURD STARMENT SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MA | Market Revenue | 123 |
| MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) Market Share TABLE 49 MARKET SHARE OF ENZYMES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) FIGURE 26 MARKET SHARE OF ENZYMES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) INDUSTRY STRUCTURE PEPTIDE HORMONES Market Leaders 125 MARKET 50 PEPTIDE HORMONES Market Share TABLE 51 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) FIGURE 27 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) THERAPEUTIC ENZYMES 130 TABLE 52 THERAPEUTIC ENZYMES 131 TABLE 54 THERAPEUTIC ENZYMES 131 TABLE 55 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE MARKET BY TYPE 134 MARKET EVENUE TABLE 55 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) MARKET BY TYPE 136 MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) MARKET BY BARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) PIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET SHARE OF CYTOKINES BY TYPE, 11-2018 (\$ MILLIONS) MARKET REVENUE ABBLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | | 124 |
| TABLE 49 MARKET SHARE OF ENZYMES BY TYPE OF MANUFACTURING PROCESSES. 2012 (%) INDUSTRY STRUCTURE PEPTIDE HORMONES Market LeaderS TABLE 50 PEPTIDE HORMONES Market Share OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) FIGURE 27 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) THERAPEUTIC ENZYMES TABLE 51 THERAPEUTIC ENZYMES TABLE 52 THERAPEUTIC ENZYMES TABLE 52 THERAPEUTIC ENZYMES TABLE 52 THERAPEUTIC ENZYMES TABLE 52 THERAPEUTIC ENZYMES TABLE 53 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE MARKET OVERVIEW MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) MARKET SHARE TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) PIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) PIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET MARKET OVERVIEW MARKET SHARE TABLE 56 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET MARKET SHARE TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, 1HROUGH 2018 (\$ MILLIONS) MARKET SHARE TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET 140 MONOCLONAL ANTIBODIES MARKET | | 124 |
| 2012 (%) 125 | Market Share | 124 |
| PROCESSES, 2012 (%) 125 INDUSTRY STRUCTURE 125 PEPTIDE HORMONES 125 Market Leaders 125 TABLE 50 PEPTIDE HORMONES 126 Market Share 128 TABLE 51 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) 130 FIGURE 27 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) 130 THERAPEUTIC ENZYMES 130 Market Share 131 TABLE 53 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) 131 FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) 131 COMPANIES, 2012 (%) 131 CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES 134 MARKET BY TYPE 134 MARKET GVERVIEW 135 MARKET REVENUE 136 TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 71HROUGH 2018 (\$ MILLIONS) 136 FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) 136 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) 137 CYTOKINES MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) 137 CYTOKINES MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) 137 CYTOKINES MARKET SHARE OF CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) 139 FIGURE 30 MARKET SHARE OF CYTOKINES BY TYPE, 7HROUGH 2018 (\$ MILLIONS) 139 FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) 139 FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2012 (%) 140 MONOCLONAL ANTIBODIES MARKET 140 MONOCLONAL ANTIBODIES MARKET 140 MONOCLONAL ANTIBODIES MARKET 140 | | 125 |
| PEPTIDE HORMONES Market Leaders TABLE 50 PERTIDE HORMONES Market Share TABLE 51 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) FIGURE 27 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) THERAPEUTIC ENZYMES TABLE 52 THERAPEUTIC ENZYMES Market Share TABLE 52 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE MARKET OF THERAPEUTIC ENZYME MANUFACTURING 131 CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE MARKET OVERVIEW MARKET REVENUE TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 7HROUGH 2018 (5 MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (5 MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET TABLE 56 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) 137 CYTOKINES MARKET TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) MARKET SHARE TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | | 125 |
| Market Leaders 125 TABLE 50 PEPTIDE HORMONES 126 Market Share 128 TABLE 51 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) 129 FIGURE 27 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) 130 THERAPEUTIC ENZYMES 130 Market Share 131 TABLE 53 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) 131 FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) 131 CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES 134 MARKET BY TYPE 134 MARKET OVERVIEW 134 MARKET REVENUE 135 TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) 136 MARKET SHARE 137 TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) 137 (%) 137 FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) 137 (%) 137 FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) 138 Market Share 140 TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIO | INDUSTRY STRUCTURE | 125 |
| TABLE 50 PEPTIDE HORMONES 126 Market Share 128 TABLE 51 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) 129 FIGURE 27 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) 130 THERAPEUTIC ENZYMES 130 Market Share 131 TABLE 53 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) 131 FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) 131 CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES 134 MARKET BY TYPE 134 MARKET BY TYPE 134 MARKET REVENUE 135 TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) 136 REGION, 2011-2018 (\$ MILLIONS) 136 MARKET SHARE 137 TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) 137 (%) 137 FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) 137 FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) 138 Market Share 138 TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) 140 <td< td=""><td>PEPTIDE HORMONES</td><td>125</td></td<> | PEPTIDE HORMONES | 125 |
| TABLE 51 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) THERAPEUTIC ENZYMES TABLE 52 THERAPEUTIC ENZYMES TABLE 52 THERAPEUTIC ENZYMES TABLE 52 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING Market Share TABLE 52 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE MARKET OVERVIEW MARKET OVERVIEW TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET MARKET OVERVIEW MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 30 MARKET FHARE OF CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) 138 TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) 139 FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) 140 FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | Market Leaders | 125 |
| TABLE 51 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) FIGURE 27 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) THERAPEUTIC ENZYMES TABLE 52 THERAPEUTIC ENZYMES Market Share 131 TABLE 53 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE MARKET OVERVIEW MARKET REVENUE TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) MARKET BASE TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) MARKET SHARE TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | TABLE 50 PEPTIDE HORMONES | 126 |
| ### 12912 (%) FIGURE 27 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) THERAPEUTIC ENZYMES TABLE 52 THERAPEUTIC ENZYMES Market Share 130 Market Share 131 TABLE 53 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) COMPANIES, 2012 (%) CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE MARKET OVERVIEW MARKET OVERVIEW MARKET REVENUE 134 **MARKET BY TYPE** TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview Market Revenue 138 TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) 139 Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) 139 Market Share 140 TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | Market Share | 128 |
| ### THERAPEUTIC ENZYMES TABLE 52 THERAPEUTIC ENZYMES 130 Market Share 131 TABLE 53 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE MARKET BY TYPE MARKET OVERVIEW 134 MARKET REVENUE TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview Market Overview 138 Market Revenue TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, 111-2018 (\$ MILLIONS) MARKET SHARE TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) 139 Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) 139 Market Share 140 TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | • | 129 |
| TABLE 52 THERAPEUTIC ENZYMES Market Share 131 TABLE 53 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE MARKET OVERVIEW 134 MARKET REVENUE TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE 137 TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview 138 MARKET GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) 139 Market Revenue TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) 139 Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) 139 Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) 139 Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) HONOCLONAL ANTIBODIES MARKET | · | 129 |
| Market Share TABLE 53 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE MARKET OVERVIEW MARKET REVENUE TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET TABLE 56 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) 138 TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | THERAPEUTIC ENZYMES | 130 |
| TABLE 53 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE MARKET OVERVIEW MARKET REVENUE TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview Market Revenue TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | TABLE 52 THERAPEUTIC ENZYMES | 130 |
| COMPANIES, 2012 (%) FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE 134 MARKET OVERVIEW MARKET REVENUE TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE 137 TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview Market Overview Market Revenue TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) MARKET SHARE TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share 138 TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share 140 TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | Market Share | 131 |
| COMPANIES, 2012 (%) CHAPTER 8 CYTOKINES AND MONOCLONAL ANTIBODIES MARKET BY TYPE MARKET OVERVIEW MARKET REVENUE TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview 138 Market Revenue TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) MARKET SHARE TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | | 131 |
| MARKET BY TYPE MARKET OVERVIEW MARKET REVENUE TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview Market Revenue TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | | 131 |
| MARKET BY TYPE MARKET OVERVIEW MARKET REVENUE TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview Market Revenue TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | | |
| MARKET OVERVIEW MARKET REVENUE TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview Market Revenue TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | | 134 |
| MARKET REVENUE TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview 138 Market Revenue TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | MARKET BY TYPE | 134 |
| TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview 138 Market Revenue TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | MARKET OVERVIEW | 134 |
| REGION, THROUGH 2018 (\$ MILLIONS) FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview 138 Market Revenue TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share 140 TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | MARKET REVENUE | 135 |
| REGION, 2011-2018 (\$ MILLIONS) MARKET SHARE TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview 138 Market Revenue 138 TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | | 136 |
| TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview 138 Market Revenue TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET | | 136 |
| (%) FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) CYTOKINES MARKET Market Overview 138 Market Revenue TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET 140 | MARKET SHARE | 137 |
| CYTOKINES MARKET Market Overview Market Revenue TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET 140 | | 137 |
| Market Overview 138 Market Revenue 138 TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share 140 TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET 140 | , | 137 |
| Market Revenue 138 TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) 139 FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) 139 Market Share 140 TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) 140 FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) 140 MONOCLONAL ANTIBODIES MARKET 140 | CYTOKINES MARKET | 137 |
| TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET 140 | Market Overview | |
| FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) Market Share 140 TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET 140 | Market Revenue | |
| Market Share 140 TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) 140 FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) 140 MONOCLONAL ANTIBODIES MARKET 140 | TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) | 139 |
| TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%)140FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%)140MONOCLONAL ANTIBODIES MARKET140 | FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) | 139 |
| FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET 140 | Market Share | 140 |
| FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) MONOCLONAL ANTIBODIES MARKET 140 | TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) | |
| MONOCLONAL ANTIBODIES MARKET 140 | | 140 |
| Market Overview 141 | • • • • | 140 |
| | Market Overview | 141 |

| TOPIC | PAGE NO. |
|--|----------|
| Market Revenue | 141 |
| TABLE 58 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPE, THROUGH 2018 (\$ MILLIONS) | 142 |
| FIGURE 33 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPE, 2011-2018 (\$ MILLIONS) | 142 |
| Market Share | 142 |
| TABLE 59 MARKET SHARE OF MONOCLONAL ANTIBODIES BY TYPE, 2012 (%) | 143 |
| FIGURE 34 MARKET SHARE OF MONOCLONAL ANTIBODIES BY TYPE, 2012 (%) | 143 |
| MARKET BY REGION | 143 |
| CYTOKINES | 144 |
| Market Overview | 144 |
| Market Revenue | 145 |
| TABLE 60 GLOBAL MARKET FOR CYTOKINES BY REGION, THROUGH 2018 (\$ MILLIONS) | 145 |
| FIGURE 35 GLOBAL MARKET FOR CYTOKINES BY REGION, 2011-2018 (\$ MILLIONS) | 145 |
| Market Share | 146 |
| TABLE 61 MARKET SHARE OF CYTOKINES BY REGION, 2012 (%) | 146 |
| FIGURE 36 MARKET SHARE OF CYTOKINES BY REGION, 2012 (%) | 146 |
| MONOCLONAL ANTIBODIES | 146 |
| Market Overview | 147 |
| Market Revenue | 148 |
| TABLE 62 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) | 148 |
| FIGURE 37 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) | 148 |
| Market Share | 149 |
| TABLE 63 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) | 149 |
| FIGURE 38 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) | 149 |
| MARKET BY MANUFACTURING PROCESS | 149 |
| CYTOKINES | 150 |
| Market Overview | 150 |
| Market Revenue | 150 |
| TABLE 64 GLOBAL MARKET FOR CYTOKINES BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 151 |
| FIGURE 39 GLOBAL MARKET FOR CYTOKINES BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (%) | 151 |
| Market Share | 151 |
| TABLE 65 MARKET SHARE OF CYTOKINES, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 152 |
| FIGURE 40 MARKET SHARE OF CYTOKINES, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 152 |
| MONOCLONAL ANTOBODIES | 152 |
| Market Overview | 152 |
| Market Revenue | 153 |
| TABLE 66 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 153 |
| FIGURE 41 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) | 153 |
| Market Share | 154 |

| TOPIC | PAGE NO. |
|--|----------|
| TABLE 67 MARKET SHARE OF MONOCLONAL ANTOBODIES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 154 |
| FIGURE 42 MARKET SHARE OF MONOCLONAL ANTOBODIES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 154 |
| INDUSTRY STRUCTURE | 155 |
| CYTOKINES | 155 |
| Market Leaders | 155 |
| TABLE 68 GLOBAL MANUFACTURERS OF CYTOKINES | 155 |
| Market Share | 156 |
| TABLE 69 MARKET SHARE OF CYTOKINES MANUFACTURING COMPANIES, 2012 (%) | 156 |
| FIGURE 43 MARKET SHARE OF CYTOKINES MANUFACTURING COMPANIES, 2012 (%) | 156 |
| MONOCLONAL ANTIBODIES | 157 |
| Market Leader | 157 |
| TABLE 70 GLOBAL MANUFACTURERS OF MONOCLONAL ANTIBODIES | 157 |
| Market Share | 158 |
| TABLE 71 MARKET SHARE OF MONOCLONAL ANTIBODIES MANUFACTURING COMPANIES, 2012 (%) | 159 |
| FIGURE 44 MARKET SHARE OF MONOCLONAL ANTIBODIES MANUFACTURING COMPANIES, 2012 (%) | 159 |
| CHAPTER 9 BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS | 161 |
| MARKET BY TYPE | 161 |
| MARKET OVERVIEW | 162 |
| MARKET REVENUE | 163 |
| TABLE 72 GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, THROUGH 2018 (\$ MILLIONS) | 164 |
| FIGURE 45 GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, 2011-2018 (\$ MILLIONS) | 164 |
| MARKET SHARE | 164 |
| TABLE 73 MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, 2012 (%) | 165 |
| FIGURE 46 MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, 2012 (%) | 165 |
| MARKET FOR BLOOD FACTORS | 165 |
| Market Overview | 166 |
| Market Revenue | 166 |
| TABLE 74 GLOBAL MARKET FOR BLOOD FACTORS BY TYPE, THROUGH 2018 (\$ MILLIONS) | 167 |
| FIGURE 47 GLOBAL MARKET FOR BLOOD FACTORS BY TYPE, THROUGH 2018 (\$ MILLIONS) | 167 |
| Market Share | 168 |
| TABLE 75 MARKET SHARE OF BLOOD FACTORS, BY TYPE, 2012 (%) | 168 |
| FIGURE 48 MARKET SHARE OF BLOOD FACTORS, BY TYPE, 2012 (%) | 168 |
| MARKET FOR VACCINES | 168 |
| Market Overview | 169 |
| Market Revenue | 170 |
| TABLE 76 GLOBAL MARKET FOR VACCINES BY TYPE, THROUGH 2018 (\$ MILLIONS) | 170 |
| FIGURE 49 GLOBAL MARKET FOR VACCINES BY TYPE, 2011-2018 (\$ MILLIONS) | 171 |
| Market Share | 171 |

| TOPIC | PAGE NO. |
|--|----------|
| TABLE 77 MARKET SHARE OF VACCINES BY TYPE, 2012 (%) | 171 |
| FIGURE 50 MARKET SHARE OF VACCINES BY TYPE, 2012 (%) | 171 |
| MARKET FOR PEPTIDE ANTIBIOTICS | 172 |
| Market Overview | 172 |
| Market Revenue | 173 |
| TABLE 78 GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPE, THROUGH 2018 (\$ MILLIONS) | 173 |
| FIGURE 51 GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPE, 2011-2018 (\$ MILLIONS) | 173 |
| Market Share | 174 |
| TABLE 79 MARKET SHARE OF PEPTIDE ANTIBIOTICS BY TYPE, 2012 (%) | 174 |
| FIGURE 52 MARKET SHARE OF PEPTIDE ANTIBIOTICS BY TYPE, 2012 (%) | 174 |
| MARKET BY REGION | 175 |
| BLOOD FACTORS | 175 |
| Market Overview | 175 |
| Market Revenue | 176 |
| TABLE 80 GLOBAL MARKET FOR BLOOD FACTORS BY REGION, THROUGH 2018 (\$ MILLIONS) | 177 |
| FIGURE 53 GLOBAL MARKET FOR BLOOD FACTORS BY REGION, 2011-2018 (\$ MILLIONS) | 177 |
| Market Share | 177 |
| TABLE 81 MARKET SHARE OF BLOOD FACTORS, BY REGION, 2012 (%) | 178 |
| FIGURE 54 MARKET SHARE OF BLOOD FACTORS, BY REGION, 2012 (%) | 178 |
| VACCINES | 178 |
| Market Overview | 178 |
| Market Revenue | 179 |
| TABLE 82 GLOBAL MARKET FOR VACCINES BY REGION, THROUGH 2018 (\$ MILLIONS) | 179 |
| FIGURE 55 GLOBAL MARKET FOR VACCINES BY REGION, 2011-2018 (\$ MILLIONS) | 179 |
| Market Share | 180 |
| TABLE 83 MARKET SHARE OF VACCINES BY REGION, 2012 (%) | 180 |
| FIGURE 56 MARKET SHARE OF VACCINES BY REGION, 2012 (%) | 180 |
| PEPTIDE ANTIBIOTICS | 181 |
| Market Overview | 181 |
| Market Revenue | 182 |
| TABLE 84 GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2018 (\$ MILLIONS) | 183 |
| FIGURE 57 GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY REGION, 2011-2018 (\$ MILLIONS) | 183 |
| Market Share | 184 |
| TABLE 85 MARKET SHARE OF PEPTIDE ANTIBIOTICS BY REGION, 2012 (%) | 184 |
| FIGURE 58 MARKET SHARE OF PEPTIDE ANTIBIOTICS BY REGION, 2012 (%) | 184 |
| MARKET BY MANUFACTURING PROCESS | 184 |
| BLOOD FACTORS | 185 |
| Market Overview | 185 |
| Market Revenue | 185 |
| TABLE 86 GLOBAL MARKET FOR BLOOD FACTORS BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 186 |

| TOPIC | PAGE NO. |
|--|----------|
| FIGURE 59 GLOBAL MARKET FOR BLOOD FACTORS BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) | 186 |
| Market Share | 186 |
| TABLE 87 MARKET SHARE OF BLOOD FACTORS BY TYPE OF MANUFACTURING PROCESS, 2012 (%) | 187 |
| FIGURE 60 MARKET SHARE OF BLOOD FACTORS BY TYPE OF MANUFACTURING PROCESS, 2012 (%) | 187 |
| VACCINES | 187 |
| Market Overview | 188 |
| Market Revenue | 188 |
| TABLE 88 GLOBAL MARKET FOR VACCINES BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 188 |
| FIGURE 61 GLOBAL MARKET FOR VACCINES BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) | 189 |
| Market Share | 189 |
| TABLE 89 MARKET SHARE OF VACCINES, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 190 |
| FIGURE 62 MARKET SHARE OF VACCINES, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 190 |
| PEPTIDE ANTIBIOTICS | 190 |
| Market Overview | 191 |
| Market Revenue | 191 |
| TABLE 90 GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 192 |
| FIGURE 63 GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) | 192 |
| Market Share | 192 |
| TABLE 91 MARKET SHARE OF PEPTIDE ANTIBIOTICS, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 193 |
| FIGURE 64 MARKET SHARE OF PEPTIDE ANTIBIOTICS, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 193 |
| INDUSTRY STRUCTURE | 193 |
| BLOOD FACTORS | 193 |
| Market Leaders | 193 |
| TABLE 92 LEADING MANUFACTURERS OF THERAPEUTIC BLOOD PRODUCTS | 194 |
| Market Share | 196 |
| TABLE 93 MARKET SHARE OF BLOOD FACTOR MANUFACTURING COMPANIES, 2012 (%) | 196 |
| FIGURE 65 MARKET SHARE OF BLOOD FACTOR MANUFACTURING COMPANIES, 2012 (%) | 197 |
| VACCINES | 197 |
| Market Leaders | 197 |
| TABLE 94 LEADING MANUFACTURERS OF VIRAL VACCINES | 197 |
| Market Share | 200 |
| TABLE 95 MARKET SHARE OF VACCINE MANUFACTURING COMPANIES, 2012 (%) | 201 |
| FIGURE 66 MARKET SHARE OF VACCINES MANUFACTURING COMPANIES, 2012 (%) | 201 |
| PEPTIDE ANTIBIOTICS | 202 |
| Market Leaders | 202 |
| TABLE 96 LEADING MANUFACTURERS OF PEPTIDE ANTIBIOTICS | 202 |
| Market Share | 203 |

| TOPIC | PAGE NO. |
|--|----------|
| TABLE 97 MARKET SHARE OF PEPTIDE ANTIBIOTIC MANUFACTURING COMPANIES, 2012 (%) | 203 |
| FIGURE 67 MARKET SHARE OF PEPTIDE ANTIBIOTIC MANUFACTURING COMPANIES, 2012 (%) | 203 |
| CHAPTER 10 PATENT ANALYSIS | 205 |
| PATENTS BY YEAR | 205 |
| TABLE 98 NUMBER OF SIGNIFICANT PATENTS, BY YEAR, JANUARY 2009-JUNE 2013 | 205 |
| FIGURE 68 NUMBER OF SIGNIFICANT PATENTS, BY YEAR, JANUARY 2009-JUNE 2013 | 205 |
| PATENTS BY TYPE/CATEGORY | 206 |
| TABLE 99 PATENTS BY CATEGORY, JANUARY 2009-JUNE 2013 | 206 |
| FIGURE 69 PATENTS BY CATEGORY, JANUARY 2009-JUNE 2013 | 206 |
| PATENTS BY COMPANY | 207 |
| TABLE 100 NUMBER OF U.S. PATENTS, BY COMPANY, JANUARY 2009- JUNE 2013 | 207 |
| PATENTS BY COUNTRY | 212 |
| TABLE 101 NUMBER OF U.S. PATENTS, BY COUNTRY, JANUARY 2009-JUNE 2013 | 212 |
| TABLE 102 PATENT SHARES, BY COUNTRY, JANUARY 2009-JUNE 2013 (%) | 213 |
| PATENTS BY ASSIGNEE | 214 |
| TABLE 103 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-JUNE 2013 | 214 |
| FIGURE 70 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-JUNE 2013 | 214 |
| CHAPTER 11 CURRENT SITUATION | 216 |
| FACTORS AFFECTING THE PROTEIN THERAPEUTICS MARKET | 216 |
| INCREASING PREVALENCE OF CHRONIC DISEASES | 216 |
| GROWING AGING POPULATION | 216 |
| LIFESTYLE CHANGES | 217 |
| NEW PRODUCT LAUNCHES | 217 |
| ADVANCEMENTS IN MANUFACTURING TECHNOLOGIES | 217 |
| PRICE CONTROLS | 218 |
| REGULATORY PRESSURES | 218 |
| ENTRY OF FOLLOW-ON-BIOLOGICS/BIOSIMILARS | 218 |
| MERGERS AND ACQUISITIONS | 219 |
| LICENSING AGREEMENTS | 219 |
| CHAPTER 12 COMPANY PROFILES | 221 |
| ABBOTT LABORATORIES | 221 |
| AFFYMAX | 221 |
| ALCON | 222 |
| ALEXION PHARMACEUTICALS | 222 |
| ALLERGAN INC | 223 |
| AMGEN | 223 |
| BAXTER HEALTHCARE | 224 |
| BAYER HEALTHCARE PHARMACEUTICALS | 224 |
| BIO PRODUCTS LABORATORY | 225 |
| BIOGEN IDEC | 225 |
| BIOTEST PHARMACEUTICALS CORPORATION | 226 |
| BOEHRINGER INGELHEIM | 226 |
| BRISTOL-MYERS SQUIBB | 227 |

| TOPIC | PAGE N |
|---|--------|
| BTG INTERNATIONAL LIMITED | |
| CANGENE CORPORATION | |
| CSL LIMITED | |
| DENDREON COPORATION | |
| EISAI CO. LTD. | |
| ELI LILLY | |
| FERRING PHARMACEUTICALS | |
| FRESENIUS KABI USA | |
| GLAXOSMITHKLINE | |
| GRIFOLS BIOLOGICALS INC | |
| HOFFMAN-LA-ROCHE | |
| HOSPIRA | |
| JANSSEN-CILAG | |
| JOHNSON & JOHNSON | |
| KAMADA LTD. | |
| KEDRION BIOPHARMACEUTICALS, SPA | |
| LUNDBECK LLC | |
| MEDIMMUNE LLC | |
| MERCK & CO, INC | |
| MERCK KGAA | |
| MYLAN INC. | |
| NABI BIOPHARMACEUTICALS (NOW BIOTA PHARMACEUTICALS) | |
| NOVARTIS | |
| NOVO NORDISK INC | |
| OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H | |
| OMRIX BIOPHARMACEUTICALS LTD | |
| PFIZER INC | |
| PROTEIN SCIENCES CORPORATION | |
| RARE DISEASE THERAPEUTICS INC. | |
| REVO BIOLOGICS | |
| SANDOZ | |
| SANOFI | |
| SEATTLE GENETICS INC. | |
| SPECTRUM PHARMACEUTICALS INC. | |
| TAKEDA PHARMACEUTICALS | |
| UCB COMPANY | |
| UPSHER SMITH LABORATORIES INC | |
| VIROPHARMA INC | |
| WATSON LABS | |
| WOCKHARDT LIMITED | |
| X-GEN PHARMS | |
| ZYMOGENETICS, INC | |
| ZIMOULINES, INC | |
| PTER 13 APPENDIX: ABBREVIATIONS | |

LIST OF TABLES

| TABLE HEADING | PAGE NO. |
|--|----------|
| SUMMARY TABLE GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS) | 6 |
| TABLE 1 EVOLUTION OF THERAPEUTIC PROTEINS | 10 |
| TABLE 2 PROTEIN DRUGS MADE BY HUMAN SOURCE EXTRACTION | 13 |
| TABLE 3 PROTEIN DRUGS MADE BY ANIMAL SOURCE EXTRACTION | 14 |
| TABLE 4 PROTEIN DRUGS MADE BY MICROBIAL FERMENTATION | 16 |
| TABLE 5 PROTEIN DRUGS MADE BY TRANSGENIC ORGANISMS | 17 |
| TABLE 6 PROTEIN DRUGS MADE BY MAMMALIAN CELL CULTURE | 18 |
| TABLE 7 PROTEIN DRUGS MADE BY INSECT CELL CULTURE | 18 |
| TABLE 8 NEW APPROVALS OF MONOCLONAL ANTIBODIES (2009-JUNE 2013) | 32 |
| TABLE 9 NEW APPROVALS OF THERAPEUTIC ENZYMES (2009-JUNE 2013) | 34 |
| TABLE 10 NEW APPROVALS OF CYTOKINES (2009-JUNE 2013) | 36 |
| TABLE 11 NEW APPROVALS OF VACCINES (2009-JUNE 2013) | 36 |
| TABLE 12 NEW APPROVALS OF BLOOD FACTORS (2009-JUNE 2013) | 39 |
| TABLE 13 NEW APPROVALS OF PEPTIDE HORMONES (2009- JUNE 2013) | 42 |
| TABLE 14 NEW DRUG APPLICATIONS/BIOLOGICAL LICENSE APPLICATIONS (2009-JUNE 2013) | 43 |
| TABLE 15 RECALLS (2009-JUNE 2013) | 45 |
| TABLE 16 SAFETY ALERTS (2009-JUNE 2013) | 49 |
| TABLE 17 NEW DEVELOPMENTS/CLINICAL TRIALS IN BLOOD PRODUCTS | 53 |
| TABLE 18 NEW DEVELOPMENTS/CLINICAL TRIALS IN VACCINES | 55 |
| TABLE 19 NEW DEVELOPMENTS/CLINICAL TRIALS IN PEPTIDE HORMONES | 58 |
| TABLE 20 NEW DEVELOPMENTS/CLINICAL TRIALS IN PEPTIDE ANTIBIOTICS | 61 |
| TABLE 21 NEW DEVELOPMENTS/CLINICAL TRIALS IN CYTOKINES | 63 |
| TABLE 22 NEW DEVELOPMENTS/CLINICAL TRIALS IN MONOCLONAL ANTIBODIES | 65 |
| TABLE 23 NEW DEVELOPMENTS/CLINICAL TRIALS IN ENZYMES | 71 |
| TABLE 24 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPE, THROUGH 2018 (\$ MILLIONS) | 79 |
| TABLE 25 MARKET SHARE OF PROTEIN THERAPEUTICS, BY TYPE, 2012 (%) | 80 |
| TABLE 26 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY REGION, THROUGH 2018 (\$ MILLIONS) | 84 |
| TABLE 27 MARKET SHARE OF PROTEIN THERAPEUTICS, BY REGION, 2012 (%) | 85 |
| TABLE 28 GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, THROUGH 2018 (\$ MILLIONS) | 87 |
| TABLE 29 MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, 2012 (%) | 88 |
| TABLE 30 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) | 90 |
| TABLE 31 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) | 91 |
| TABLE 32 GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2018 (\$ MILLIONS) | 93 |
| TABLE 33 MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, 2012 (%) | 94 |
| TABLE 34 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 99 |
| TABLE 35 MARKET SHARE OF PROTEIN THERAPEUTICS BY TYPE OF MANUFACTURING PROCESS, 2012 (%) | 100 |
| TABLE 36 GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES, THROUGH 2018 (\$ MILLIONS) | 104 |

| TABLE HEADING | PAGE NO. |
|--|----------|
| TABLE 37 MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES, 2012 (%) | 105 |
| TABLE 38 GLOBAL MARKET FOR PEPTIDE HORMONES BY TYPE, THROUGH 2018 (\$ MILLIONS) | 108 |
| TABLE 39 MARKET SHARE OF PEPTIDE HORMONES BY TYPE, 2012 (%) | 109 |
| TABLE 40 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY TYPE, THROUGH 2018 (\$ MILLIONS) | 111 |
| TABLE 41 MARKET SHARE OF THERAPEUTIC ENZYMES BY TYPE, 2012 (%) | 112 |
| TABLE 42 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, THROUGH 2018 (\$ MILLIONS) | 114 |
| TABLE 43 MARKET SHARE OF PEPTIDE HORMONES BY REGION, 2012 (%) | 115 |
| TABLE 44 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, THROUGH 2018 (\$ MILLIONS) | 117 |
| TABLE 45 MARKET SHARE OF THERAPEUTIC ENZYMES BY REGION, 2012 (%) | 118 |
| TABLE 46 GLOBAL MARKET FOR PEPTIDE HORMONES BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 121 |
| TABLE 47 MARKET SHARE OF PEPTIDE HORMONES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 122 |
| TABLE 48 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 124 |
| TABLE 49 MARKET SHARE OF ENZYMES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 125 |
| TABLE 50 PEPTIDE HORMONES | 126 |
| TABLE 51 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) | 129 |
| TABLE 52 THERAPEUTIC ENZYMES | 130 |
| TABLE 53 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) | 131 |
| TABLE 54 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) | 136 |
| TABLE 55 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) | 137 |
| TABLE 56 GLOBAL MARKET FOR CYTOKINES BY TYPE, THROUGH 2018 (\$ MILLIONS) | 139 |
| TABLE 57 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) | 140 |
| TABLE 58 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPE, THROUGH 2018 (\$ MILLIONS) | 142 |
| TABLE 59 MARKET SHARE OF MONOCLONAL ANTIBODIES BY TYPE, 2012 (%) | 143 |
| TABLE 60 GLOBAL MARKET FOR CYTOKINES BY REGION, THROUGH 2018 (\$ MILLIONS) | 145 |
| TABLE 61 MARKET SHARE OF CYTOKINES BY REGION, 2012 (%) | 146 |
| TABLE 62 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, THROUGH 2018 (\$ MILLIONS) | 148 |
| TABLE 63 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) | 149 |
| TABLE 64 GLOBAL MARKET FOR CYTOKINES BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 151 |
| TABLE 65 MARKET SHARE OF CYTOKINES, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 152 |
| TABLE 66 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 153 |
| TABLE 67 MARKET SHARE OF MONOCLONAL ANTOBODIES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 154 |
| TABLE 68 GLOBAL MANUFACTURERS OF CYTOKINES | 155 |

| TABLE HEADING | PAGE NO. |
|--|----------|
| TABLE 69 MARKET SHARE OF CYTOKINES MANUFACTURING COMPANIES, 2012 (%) | 156 |
| TABLE 70 GLOBAL MANUFACTURERS OF MONOCLONAL ANTIBODIES | 157 |
| TABLE 71 MARKET SHARE OF MONOCLONAL ANTIBODIES MANUFACTURING COMPANIES, 2012 (%) | 159 |
| TABLE 72 GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, THROUGH 2018 (\$ MILLIONS) | 164 |
| TABLE 73 MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, 2012 (%) | 165 |
| TABLE 74 GLOBAL MARKET FOR BLOOD FACTORS BY TYPE, THROUGH 2018 (\$ MILLIONS) | 167 |
| TABLE 75 MARKET SHARE OF BLOOD FACTORS, BY TYPE, 2012 (%) | 168 |
| TABLE 76 GLOBAL MARKET FOR VACCINES BY TYPE, THROUGH 2018 (\$ MILLIONS) | 170 |
| TABLE 77 MARKET SHARE OF VACCINES BY TYPE, 2012 (%) | 171 |
| TABLE 78 GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPE, THROUGH 2018 (\$ MILLIONS) | 173 |
| TABLE 79 MARKET SHARE OF PEPTIDE ANTIBIOTICS BY TYPE, 2012 (%) | 174 |
| TABLE 80 GLOBAL MARKET FOR BLOOD FACTORS BY REGION, THROUGH 2018 (\$ MILLIONS) | 177 |
| TABLE 81 MARKET SHARE OF BLOOD FACTORS, BY REGION, 2012 (%) | 178 |
| TABLE 82 GLOBAL MARKET FOR VACCINES BY REGION, THROUGH 2018 (\$ MILLIONS) | 179 |
| TABLE 83 MARKET SHARE OF VACCINES BY REGION, 2012 (%) | 180 |
| TABLE 84 GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2018 (\$ MILLIONS) | 183 |
| TABLE 85 MARKET SHARE OF PEPTIDE ANTIBIOTICS BY REGION, 2012 (%) | 184 |
| TABLE 86 GLOBAL MARKET FOR BLOOD FACTORS BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 186 |
| TABLE 87 MARKET SHARE OF BLOOD FACTORS BY TYPE OF MANUFACTURING PROCESS, 2012 (%) | 187 |
| TABLE 88 GLOBAL MARKET FOR VACCINES BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 188 |
| TABLE 89 MARKET SHARE OF VACCINES, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 190 |
| TABLE 90 GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPES OF MANUFACTURING PROCESSES, THROUGH 2018 (\$ MILLIONS) | 192 |
| TABLE 91 MARKET SHARE OF PEPTIDE ANTIBIOTICS, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 193 |
| TABLE 92 LEADING MANUFACTURERS OF THERAPEUTIC BLOOD PRODUCTS | 194 |
| TABLE 93 MARKET SHARE OF BLOOD FACTOR MANUFACTURING COMPANIES, 2012 (%) | 196 |
| TABLE 94 LEADING MANUFACTURERS OF VIRAL VACCINES | 197 |
| TABLE 95 MARKET SHARE OF VACCINE MANUFACTURING COMPANIES, 2012 (%) | 201 |
| TABLE 96 LEADING MANUFACTURERS OF PEPTIDE ANTIBIOTICS | 202 |
| TABLE 97 MARKET SHARE OF PEPTIDE ANTIBIOTIC MANUFACTURING COMPANIES, 2012 (%) | 203 |
| TABLE 98 NUMBER OF SIGNIFICANT PATENTS, BY YEAR, JANUARY 2009-JUNE 2013 | 205 |
| TABLE 99 PATENTS BY CATEGORY, JANUARY 2009-JUNE 2013 | 206 |
| TABLE 100 NUMBER OF U.S. PATENTS, BY COMPANY, JANUARY 2009- JUNE 2013 | 207 |
| TABLE 101 NUMBER OF U.S. PATENTS, BY COUNTRY, JANUARY 2009-JUNE 2013 | 212 |
| TABLE 102 PATENT SHARES, BY COUNTRY, JANUARY 2009-JUNE 2013 (%) | 213 |
| TABLE 103 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-JUNE 2013 | 214 |

LIST OF FIGURES

| FIGURE TITLE | PAGE NO. |
|---|----------|
| SUMMARY FIGURE GLOBAL REVENUE OF PROTEIN THERAPEUTICS MARKET, 2011-2018 (\$ MILLIONS) | 7 |
| FIGURE 1 GLOBAL MARKET FOR PROTEIN THERAPEUTICS, BY TYPE, THROUGH 2018 (\$ MILLIONS) | 79 |
| FIGURE 2 MARKET SHARE OF PROTEIN THERAPEUTICS, BY TYPE, 2012 (%) | 80 |
| FIGURE 3 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY REGION, 2011-2018 (\$ MILLIONS) | 84 |
| FIGURE 4 MARKET SHARE OF PROTEIN THERAPEUTICS, BY REGION, 2012 (%) | 85 |
| FIGURE 5 GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, 2011-2018 (\$ MILLIONS) | 87 |
| FIGURE 6 MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES BY REGION, 2012 (%) | 88 |
| FIGURE 7 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) | 90 |
| FIGURE 8 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) | 91 |
| FIGURE 9 GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, 2011-2018 (\$ MILLIONS) | 93 |
| FIGURE 10 MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS BY REGION, 2012 (%) | 94 |
| FIGURE 11 GLOBAL MARKET FOR PROTEIN THERAPEUTICS BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) | 100 |
| FIGURE 12 MARKET SHARE OF PROTEIN THERAPEUTICS BY TYPE OF MANUFACTURING PROCESS, 2012 (%) | 101 |
| FIGURE 13 GLOBAL MARKET FOR PEPTIDE HORMONES AND THERAPEUTIC ENZYMES, 2011-2018 (\$ MILLIONS) | 104 |
| FIGURE 14 MARKET SHARE OF PEPTIDE HORMONES AND THERAPEUTIC ENZYMES, 2012 (%) | 105 |
| FIGURE 15 GLOBAL MARKET FOR PEPTIDE HORMONES BY TYPE, 2011-2018 (\$ MILLIONS) | 108 |
| FIGURE 16 MARKET SHARE OF PEPTIDE HORMONES BY TYPE, 2012 (%) | 109 |
| FIGURE 17 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY TYPE, THROUGH 2018 (\$ MILLIONS) | 111 |
| FIGURE 18 MARKET SHARE OF THERAPEUTIC ENZYMES BY TYPE, 2012 (%) | 112 |
| FIGURE 19 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, THROUGH 2018 (\$ MILLIONS) | 114 |
| FIGURE 20 MARKET SHARE OF PEPTIDE HORMONES BY REGION, 2012 (%) | 115 |
| FIGURE 21 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, 2011-2018 (\$ MILLIONS) | 117 |
| FIGURE 22 MARKET SHARE OF THERAPEUTIC ENZYMES BY REGION, 2012 (%) | 118 |
| FIGURE 23 GLOBAL MARKET FOR PEPTIDE HORMONES BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) | 121 |
| FIGURE 24 MARKET SHARE OF PEPTIDE HORMONES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 122 |
| FIGURE 25 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) | 124 |
| FIGURE 26 MARKET SHARE OF ENZYMES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 125 |
| FIGURE 27 MARKET SHARE OF PEPTIDE HORMONES MANUFACTURING COMPANIES, 2012 (%) | 129 |
| FIGURE 28 MARKET SHARE OF THERAPEUTIC ENZYME MANUFACTURING COMPANIES, 2012 (%) | 131 |

| FIGURE 29 GLOBAL MARKET FOR CYTOKINES AND MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) | 136 |
|--|-----|
| | 233 |
| FIGURE 30 MARKET SHARE OF CYTOKINES AND MONOCLONAL ANTIBODIES, 2012 (%) | 137 |
| FIGURE 31 GLOBAL MARKET FOR CYTOKINES BY TYPE, 2011-2018 (\$ MILLIONS) | 139 |
| FIGURE 32 MARKET SHARE OF CYTOKINES BY TYPE, 2012 (%) | 140 |
| FIGURE 33 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPE, 2011-2018 (\$ MILLIONS) | 142 |
| FIGURE 34 MARKET SHARE OF MONOCLONAL ANTIBODIES BY TYPE, 2012 (%) | 143 |
| FIGURE 35 GLOBAL MARKET FOR CYTOKINES BY REGION, 2011-2018 (\$ MILLIONS) | 145 |
| FIGURE 36 MARKET SHARE OF CYTOKINES BY REGION, 2012 (%) | 146 |
| FIGURE 37 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY REGION, 2011-2018 (\$ MILLIONS) | 148 |
| FIGURE 38 MARKET SHARE OF MONOCLONAL ANTIBODIES BY REGION, 2012 (%) | 149 |
| FIGURE 39 GLOBAL MARKET FOR CYTOKINES BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (%) | 151 |
| FIGURE 40 MARKET SHARE OF CYTOKINES, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 152 |
| FIGURE 41 GLOBAL MARKET FOR MONOCLONAL ANTIBODIES BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) | 153 |
| FIGURE 42 MARKET SHARE OF MONOCLONAL ANTOBODIES BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 154 |
| FIGURE 43 MARKET SHARE OF CYTOKINES MANUFACTURING COMPANIES, 2012 (%) | 156 |
| FIGURE 44 MARKET SHARE OF MONOCLONAL ANTIBODIES MANUFACTURING COMPANIES, 2012 (%) | 159 |
| FIGURE 45 GLOBAL MARKET FOR BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, 2011-2018 (\$ MILLIONS) | 164 |
| FIGURE 46 MARKET SHARE OF BLOOD FACTORS, VACCINES AND PEPTIDE ANTIBIOTICS, 2012 (%) | 165 |
| FIGURE 47 GLOBAL MARKET FOR BLOOD FACTORS BY TYPE, THROUGH 2018 (\$ MILLIONS) | 167 |
| FIGURE 48 MARKET SHARE OF BLOOD FACTORS, BY TYPE, 2012 (%) | 168 |
| FIGURE 49 GLOBAL MARKET FOR VACCINES BY TYPE, 2011-2018 (\$ MILLIONS) | 171 |
| FIGURE 50 MARKET SHARE OF VACCINES BY TYPE, 2012 (%) | 171 |
| FIGURE 51 GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPE, 2011-2018 (\$ MILLIONS) | 173 |
| FIGURE 52 MARKET SHARE OF PEPTIDE ANTIBIOTICS BY TYPE, 2012 (%) | 174 |
| FIGURE 53 GLOBAL MARKET FOR BLOOD FACTORS BY REGION, 2011-2018 (\$ MILLIONS) | 177 |
| FIGURE 54 MARKET SHARE OF BLOOD FACTORS, BY REGION, 2012 (%) | 178 |
| FIGURE 55 GLOBAL MARKET FOR VACCINES BY REGION, 2011-2018 (\$ MILLIONS) | 179 |
| FIGURE 56 MARKET SHARE OF VACCINES BY REGION, 2012 (%) | 180 |
| FIGURE 57 GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY REGION, 2011-2018 (\$ MILLIONS) | 183 |
| FIGURE 58 MARKET SHARE OF PEPTIDE ANTIBIOTICS BY REGION, 2012 (%) | 184 |
| FIGURE 59 GLOBAL MARKET FOR BLOOD FACTORS BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) | 186 |
| FIGURE 60 MARKET SHARE OF BLOOD FACTORS BY TYPE OF MANUFACTURING PROCESS, 2012 (%) | 187 |
| FIGURE 61 GLOBAL MARKET FOR VACCINES BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) | 189 |

| FIGURE TITLE | PAGE NO. |
|--|----------|
| FIGURE 62 MARKET SHARE OF VACCINES, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 190 |
| FIGURE 63 GLOBAL MARKET FOR PEPTIDE ANTIBIOTICS BY TYPES OF MANUFACTURING PROCESSES, 2011-2018 (\$ MILLIONS) | 192 |
| FIGURE 64 MARKET SHARE OF PEPTIDE ANTIBIOTICS, BY TYPE OF MANUFACTURING PROCESSES, 2012 (%) | 193 |
| FIGURE 65 MARKET SHARE OF BLOOD FACTOR MANUFACTURING COMPANIES, 2012 (%) | 197 |
| FIGURE 66 MARKET SHARE OF VACCINES MANUFACTURING COMPANIES, 2012 (%) | 201 |
| FIGURE 67 MARKET SHARE OF PEPTIDE ANTIBIOTIC MANUFACTURING COMPANIES, 2012 (%) | 203 |
| FIGURE 68 NUMBER OF SIGNIFICANT PATENTS, BY YEAR, JANUARY 2009-JUNE 2013 | 205 |
| FIGURE 69 PATENTS BY CATEGORY, JANUARY 2009-JUNE 2013 | 206 |
| FIGURE 70 NUMBER OF PATENTS BY ASSIGNEE, JANUARY 2009-JUNE 2013 | 214 |